newsfilter.io

Drug Manufacturers - General — industry outlook

  • Period: 2026-08-30 to 2026-09-20
  • Events: 12
  • Generated: 2026-09-20T06:30:00.003Z

Revenue Growth Trajectories and LOE Mitigation

Companies project a shift from historical double-digit growth to sustainable long-term ranges, with a specific focus on replenishing portfolios hit by significant Loss of Exclusivity (LOE) events.

  • Long-Term Targets: Johnson & Johnson (JNJ) and Merck (MRK) are anchoring growth expectations to long-term ranges, with JNJ targeting 5–7% annual revenue growth and projecting a "clear line of sight to double-digit" enterprise growth by the end of the decade (2030). Merck (MRK) has upgraded its non-risk-adjusted revenue ambition to exceed $70 billion from its human health product suite by the mid-2030s, citing upside from new assets like INT and MK2010 not fully included in the base.
  • LOE Absorption: Pfizer (PFE) expects new products and business development assets with an annualized run rate of ~$13 billion growing at 20%+ to offset Lost Expiration Events (LOEs) from the current fiscal year through 2027. Johnson & Johnson (JNJ) faces ~$4–$4.5 billion in LOEs in 2027 (including Xarelto, PAH franchise, Symphony, and Stellara) but maintains confidence in navigating this with volume-driven growth.
  • Growth Drivers: Amgen (AMGN) anticipates durable growth well into the next decade, driven by six key commercial drivers that contributed 26% year-over-year growth in Q2 2026. Eli Lilly (LLY) aims to capture a broader market rather than zero-sum share battles, targeting >50% steady-state share in oral GLP-1 starts over the next 18–24 months, while JNJ (JNJ) targets $50 billion in oncology sales (up from ~$30 billion) by 2030.

Obesity and Weight Management Strategy

The industry is converging on a "spectrum" approach to obesity, emphasizing retention, monthly/longer-acting dosing, and combination therapies to address high attrition rates and unmet patient needs.

  • Retention and Differentiation: Amgen (AMGN) and Eli Lilly (LLY) are positioning their next-generation assets (Meritide and Elora Lintide/Fondeo) to solve the ~50% patient discontinuation rate seen with weekly injectables. Amgen (AMGN) highlights Meritide's 8-week or quarterly dosing and ~20% weight loss data, while Lilly (LLY) targets a >50% steady-state share for its oral GLP-1 (Fondeo) with a broad portfolio covering entry, maintenance, and intensification needs.
  • Portfolio Expansion: Pfizer (PFE) is advancing its Mazira portfolio, running 10 Phase 3 studies in 2024 including monthly GLP-1 maintenance and Amylin+GLP-1 combinations, aiming to capture share from existing weekly maintenance patients. Eli Lilly (LLY) views the market as needing multiple mechanisms (GLP-1, GIP, multi-agonists) and forms to address the "N of 1" consumer needs, with Fondeo expected to expand the total addressable market ex-U.S. rather than cannibalize injectable volumes.
  • Market Entry Decisions: Johnson & Johnson (JNJ) explicitly decided against entering the GLP/Obesity market, citing a lack of "acute insight" or advantage against established competitors and noting that current entry would not advance patient care sufficiently.

Payer Access, Pricing Dynamics, and Medicare Policy

Stakeholders are navigating a complex landscape of pricing erosion, employer coverage volatility, and the emerging impact of the Medicare $50 out-of-pocket cap.

  • Pricing Erosion vs. Volume: Johnson & Johnson (JNJ) anticipates 3%–4% annual price erosion in pharmaceuticals, necessitating volume-driven growth to offset price declines. Eli Lilly (LLY) projects that evidence of direct health economics savings (~$600/month by 12 months) will shift employer P&L calculus, moving coverage from stagnant ~50% rates to active inclusion.
  • Medicare and Commercial Access: Eli Lilly (LLY) views the Medicare Bridge program's $50 out-of-pocket cap as a critical driver, projecting strong uptake and a net positive impact on the Medicare system due to cost savings. However, Lilly (LLY) acknowledges persistent friction in commercial plans with variable prior authorization criteria, while Merck (MRK) anticipates bipartisan momentum for PBM reform and 340B changes. Pfizer (PFE) notes that 340B resolution remains unlikely soon, with a new pilot program launching in January 2027 that may impact key products like Eliquis and Ibrance.
  • Commercial Coverage Volatility: Eli Lilly (LLY) reports that commercial employer coverage for obesity treatments remains stagnant at ~50%, with some employers removing coverage, though new discussions are ongoing. Pfizer (PFE) and Merck (MRK) view the 340B pilot program starting in 2027 as a significant variable with undetermined financial impact.

Geopolitics, Global Competition, and Supply Chain

Executives are adjusting strategies to account for rising Chinese innovation, supply chain resilience, and cross-border regulatory risks.

  • Rise of Chinese Competitors: Pfizer (PFE) warns of the rise of Chinese multinational pharma companies by the end of the decade, citing 3x faster development speed and 50% lower costs, necessitating a shift to AI-driven operational efficiency. Johnson & Johnson (JNJ) acknowledges China's R&D investment has risen to 30% (from 9% 15 years ago) but maintains U.S. leadership in cutting-edge innovation.
  • China-Specific Headwinds: Johnson & Johnson (JNJ) faces specific regulatory headwinds in the electrophysiology (EP) market in China due to Volume-Based Procurement (VBP) expected to impact pricing later in the year and bleed into 2027. Eli Lilly (LLY) anticipates generic semaglutide entry in ex-U.S. markets like India, Canada, and Brazil, expecting it to expand total market volume similar to historical endocrine patterns.
  • Geopolitical Friction: Pfizer (PFE) identifies dual-sided political friction regarding licensing deals between the U.S. and China as a risk, while Merck (MRK) is maintaining a global sourcing strategy to mitigate interference. Johnson & Johnson (JNJ) cites the ongoing conflict in the Middle East as a significant, unpredictable headwind affecting healthcare provision and investment in the region.

Strategic Capital Allocation and M&A Discipline

The industry is pivoting toward disciplined, science-led investments, with a clear emphasis on cash-on-cash returns and avoiding "desperation" deals.

  • Capital Efficiency: Amgen (AMGN) is committed to maintaining a top-tier margin company (FY2026 guidance of 45%–46%) while flexing margins slightly downward from peak levels (formerly in the 50s) to fund value-creating investments. Johnson & Johnson (JNJ) expects to generate approximately $21 billion in free cash flow in 2026, committing to a $55 billion investment in U.S. capabilities over the next four years.
  • M&A Philosophy: Merck (MRK) and Amgen (AMGN) maintain a "high bar" for external assets, prioritizing strategic fit and cash-on-cash returns over filling pipeline gaps. Pfizer (PFE) cites leverage constraints (~2.7x) limiting new M&A capacity to ~$6 billion annually, focusing instead on maximizing the value of its $80 billion in prior BD investments.
  • Innovation Investment: Johnson & Johnson (JNJ) aims to introduce one new therapeutic invention annually for MedTech over the next three years, while Amgen (AMGN) plans a "sweeping" Phase III program for Maritide involving roughly a dozen trials to establish market position.